Cureus | Data from a Completed Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

Data from a Completed Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2


Abstract

ARRY-380 is a potent and selective oral small molecule inhibitor of HER2
Poster
non-peer-reviewed

Data from a Completed Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2


Author Information


PDF Share